Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

DaVita HealthCare Partner (NY:DVA)

177.41 -3.00 (-1.66%)
Delayed Quote Updated: 1:29 PM EDT, Oct 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about DaVita HealthCare Partner

< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
News headline image
Siemens Healthineers, GE Healthcare Studying Potential Deals With Medtronic's Spun Off Units ↗
 
Via Benzinga
If You Invested $100 In This Stock 20 Years Ago, You Would Have $900 Today ↗
 
Via Benzinga
News headline image
Warren Buffett Now Owns 20% or More of These 5 Companies ↗
Which are these big Buffett bets are the best picks for investors? 
Via The Motley Fool
$1000 Invested In This Stock 20 Years Ago Would Be Worth $8,500 Today ↗
 
Via Benzinga
News headline image
$1000 Invested In DaVita 20 Years Ago Would Be Worth This Much Today ↗
DaVita (NYSE:DVA) has outperformed the market over the past 20 years by 3.82% on an annualized basis producing an average annual return of 11.29%. Currently, DaVita has a market capitalization of $6.29... 
Via Benzinga
News headline image
DaVita Earnings Perspective: Return On Capital Employed ↗
Pulled from Benzinga Pro data, DaVita (NYSE:DVA) showed a loss in earnings since Q2, totaling $164.69 million. Sales, on the other hand, increased by 0.75% to $2.95 billion during Q3. 
Via Benzinga
News headline image
DaVita (DVA) Q3 2022 Earnings Call Transcript ↗
DVA earnings call for the period ending September 30, 2022. 
Via The Motley Fool
News headline image
Around $134 Million Bet On This Stock Up 46% Year-To-Date? 3 Stocks Insiders Are Buying ↗
Although US stocks closed lower on Tuesday, there were a few notable insider trades. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Monday ↗
  During Monday's session, 96 stocks hit new 52-week lows. 
Via Benzinga
News headline image
Analyst Ratings for DaVita ↗
Over the past 3 months, 5 analysts have published their opinion on DaVita (NYSE:DVA) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Chevron To Rally Around 21%? Here Are 5 Other Price Target Changes For Monday ↗
Raymond James raised Chevron Corporation (NYSE: CVX) price target from $188 to $215. Raymond James analyst Justin Jenkins maintained the stock with an Outperform rating. Chevron shares fell 1.1% to... 
Via Benzinga
News headline image
Weibo, XPeng, Li Auto And Other Big Losers From Friday ↗
U.S. stocks closed higher on Friday, with the Dow Jones gaining more than 800 points. Here is the list of some big stocks recording losses in the previous session. 
Via Benzinga
News headline image
Why Pinterest Shares Jumped Around 14%; Here Are 69 Biggest Movers From Friday ↗
Gainers Quanergy Systems, Inc. (NASDAQ: QNGY) jumped 153.9% to close at $3.30 on Friday. 
Via Benzinga
News headline image
Nasdaq Climbs 275 Points; S&P 500 Rises Over 2% ↗
U.S. stocks extended gains toward the end of trading, with the Nasdaq Composite surging more than 200 points on Friday. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
Gainers 
Via Benzinga
News headline image
$100 Invested In This Stock 20 Years Ago Would Be Worth $900 Today ↗
DaVita (NYSE:DVA) has outperformed the market over the past 20 years by 4.09% on an annualized basis producing an average annual return of 11.52%. Currently, DaVita has a market capitalization of $6.63... 
Via Benzinga
News headline image
Dow Jumps 600 Points; Crude Oil Down Over 1% ↗
U.S. stocks extended gains midway through trading, with the Dow Jones surging more than 600 points on Friday. 
Via Benzinga
News headline image
2 Market-Moving Stocks You Can't Afford to Ignore ↗
Friday's market action saw volatility both upward and downward. 
Via The Motley Fool
News headline image
Why Edwards Lifesciences Shares Are Trading Lower By Around 17%? Here Are 47 Stocks Moving In Friday's Mid-Day Session ↗
Gainers Quanergy Systems, Inc. (NASDAQ: QNGY) surged 179% to $3.6301. 
Via Benzinga
News headline image
US Stocks Mostly Higher; Dow Surges 300 Points ↗
U.S. stocks traded mostly higher this morning, with the Dow Jones surging more than 300 points on Friday. 
Via Benzinga
News headline image
Dialysis Provider DaVita Slashes FY22 Earnings Outlook Citing Continued Pandemic Impact, Shares Fall ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
Gainers Nuvalent (NASDAQ:NUVL) stock increased by 15.9% to $25.5 during Friday's pre-market session. The company's market cap stands at $1.2 billion. 
Via Benzinga
News headline image
Recap: DaVita Q3 Earnings ↗
DaVita (NYSE:DVA) reported its Q3 earnings results on Friday, October 28, 2022 at 06:30 AM. Here's what investors need to know about the announcement. Earnings DaVita missed estimated earnings by... 
Via Benzinga
News headline image
Earnings Scheduled For October 28, 2022 ↗
Companies Reporting Before The Bell • TAL Education (NYSE:TAL) is projected to report quarterly earnings at $0.01 per share on revenue of $242.62 million. 
Via Benzinga
News headline image
DaVita's Earnings: A Preview ↗
DaVita (NYSE:DVA) is set to give its latest quarterly earnings report on Friday, 2022-10-28. Here's what investors need to know before the announcement. Analysts estimate that DaVita will report an... 
Via Benzinga
News headline image
7 Warren Buffett Stocks to Buy and Hold for the Next Decade ↗
Intelligent investors know that purchasing Warren Buffett stocks to buy and hold will work in the long-term. 
Via InvestorPlace
Mighty Mitochondria: This Company is Developing A Novel Drug for Kidney Disease By Targeting The Powerhouse Of Human Cells
You may remember learning that mitochondria are the powerhouse of the cells, but do you know the dangers that result if these cell superheroes get sick? 
Via TheNewswire.com
News headline image
Mighty Mitochondria: This Company is Developing A Novel Drug for Kidney Disease By Targeting The Powerhouse Of Human Cells ↗
You may remember learning that mitochondria are the powerhouse of the cells, but do you know the dangers that result if these cell superheroes get sick?  
Via Benzinga
News headline image
The 7 Most Undervalued Mid-Cap Stocks to Buy Now ↗
Here are some of the most undervalued mid-cap stocks to buy now. 
Via InvestorPlace
< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.